Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

iBio Is Now Lagging in Another Area

By Larry Ramer, InvestorPlace Contributor

iBio's leading vaccine and its therapy appear to be too far behind the competition to generate much revenue for IBIO stock.

4 Pharmaceutical Stocks With Deep Pipelines

By Larry Ramer, InvestorPlace Contributor

Coronavirus vaccines get all the attention, but these four pharmaceutical stocks benefit from equipment, drug and test kit developments.

Sorrento’s Covid-19 Test, Acquisitions Should Help SRNE Stock Surge

By Larry Ramer, InvestorPlace Contributor

Sorrento's COVID-19 test appears to be superior to competing diagnostics, and it just made a good acquisition, while its overall strategy is sound.

Contracts in Developing Countries Bode Well for GE Stock

By Larry Ramer, InvestorPlace Contributor

Recent developments show that developing countries are upgrading their electrical equipment ,while developed nations will have to continue to rely on natural gas. Those trends are positive for GE stock.

Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally

By Larry Ramer, InvestorPlace Contributor

Strong sales of Gilead's successful novel coronavirus drug, remdesivir, will ultimately lift GILD stock and reward shareholders.

Load More